CGT9486-21-301
Trial Overview
Official Title
A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMORS
Study Purpose
The purpose of this part of the research study is to evaluate how CGT9486 plus sunitinib affects GIST compared to just treatment with sunitinib alone.
Diagnosis
Gastrointestinal Stromal Tumors that cannot be surgically removed, have come back after initial treatment, or have spread to other parts of the bodyEligibility
Must have locally advanced, metastatic, and/or unresectable GIST, and have received prior therapy with imatinib.
Intervention
CGT9486+SUNITINIB VS SUNITINIB
For more information visit Clinicaltrials.gov
Key Participation Requirements
Trial Location(s)
Gender
Male or Female
Age
19 and Older
Enrollment Status
Recruiting
Phase
Phase III